Filing Flows › Alkermes (ALKS) › Q3 2026 › vs Q3 2025
Alkermes (ALKS) Q3 2026 vs Q3 2025 (year over year)
Alkermes's revenue rose $85.9M (+22%) from $394M in Q3 2025 to $480M in Q3 2026. The biggest changes: Royalty −$4.8M (-7%). Operating margin 7.5% against 22.6% (-15.1 pts).
Alkermes, Q3 2026: revenue $480M (+22% year over year), operating margin 7.5%, net earnings $16.3M, operating cash flow $93.5M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 7.5% | 22.6% | -15.1 pts |
| Net margin | 3.4% | 21.0% | -17.6 pts |
| Free cash flow margin | 18.8% | 21.4% | -2.6 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Vivitrol | $128M | $121M | $6.4M | +5% |
| Aristada and Aristada Initio | $104M | $98.0M | $5.8M | +6% |
| LYBALVI | $95.9M | $98.2M | −$2.3M | -2% |
| Royalty | $63.2M | $68.0M | −$4.8M | -7% |
| Revenue | $480M | $394M | $85.9M | +22% |
| Operating profit | $36.0M | $89.1M | −$53.1M | -60% |
| Costs & expenses | $444M | $305M | $139M | +46% |
| Pre-tax earnings | $14.7M | $101M | −$86.0M | -85% |
| Other expense, net | $21.3M | −$11.7M | $33.0M | — |
| Cost of revenue | $94.2M | $51.6M | $42.6M | +83% |
| Research & development | $121M | $81.7M | $39.4M | +48% |
| Income tax benefit | $1.6M | −$18.0M | $19.5M | — |
| Net earnings | $16.3M | $82.8M | −$66.5M | -80% |
| Depreciation & amortization | $27.2M | $8.1M | $19.1M | +236% |
| Share-based compensation | $26.7M | $24.7M | $2.1M | +8% |
| Working capital & other | $23.3M | −$13.8M | $37.1M | — |
| Operating cash flow | $93.5M | $102M | −$8.2M | -8% |
| Free cash flow (OCF − capex) | $90.1M | $84.4M | $5.7M | +7% |
| Capital expenditures | $3.4M | $17.3M | −$13.9M | -80% |
Questions
How much did Alkermes's revenue grow year over year in Q3 2026?
Alkermes's revenue rose $85.9M (+22%) from $394M in Q3 2025 to $480M in Q3 2026.
What drove Alkermes's revenue change in Q3 2026?
Royalty −$4.8M (-7%).